- Poster presentation
- Open Access
P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
Retrovirology volume 6, Article number: P390 (2009)
The native envelope gp160 trimer of HIV-1 is thought to shield vulnerable epitopes that could otherwise elicit effectively neutralizing antibodies. However, little is known about the prevalence of naturally occurring cross-reactive neutralizing activity in serum of HIV-1 infected individuals.
Here we studied 35 participants of the Amsterdam Cohort Studies on HIV-1 infection (20 long-term non-progressors (LTNP) and 15 progressors) for the presence of cross-reactive neutralizing activity in their sera at 2 and 4 years after seroconversion (SC). Neutralizing activity was tested in a pseudovirus assay, against a panel of HIV-1 envelope variants from subtype A, B, C, and D.
Already at year 2 post-SC, 7 out of 35 individuals (20%) had cross-reactive neutralizing activity, which increased to 11 individuals (31%) at 4 years post-SC. There was no difference in the prevalence of cross-reactive neutralizing serum activity between LTNP and progressors. Interestingly, high plasma viral RNA load and low CD4+ cell count at set-point were associated with early development of cross-reactive neutralizing activity. Neutralization titers in serum increased during the course of infection for 91% of individuals studied here, albeit less rapidly for those who did not develop cross-reactive neutralizing activity.
Overall, we here demonstrate a relatively high prevalence of cross-reactive neutralizing activity in HIV-1 infected individuals, which increased with duration of infection. These data may imply that immunogenicity of the native envelope spike of HIV-1 for eliciting cross-reactive humoral immune responses may be better than previously anticipated.
About this article
Cite this article
van Gils, M., Euler, Z., Schweighardt, B. et al. P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression. Retrovirology 6, P390 (2009). https://doi.org/10.1186/1742-4690-6-S3-P390
- Slow Disease Progression
- Neutralization Titer
- Neutralize Serum
- Envelope Gp160
- Envelope Variant